Aradigm increases SmartMist production:
This article was originally published in Clinica
Aradigm is scaling-up production of its SmartMist drug delivery system for a 1997 launch following 510(k) clearance by the US FDA. Phase I clinical trials for the inhalation delivery of morphine using the company's AERx system are under way and the company is conducting clinical feasibility studies for insulin delivery and diagnostic pulmonary imaging. The Californian company raised $24.7 million in its IPO in June (see Clinica No 713, p 15). Aradigm's six-month net losses were $3.7 million against revenues of $172,500.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.